Share on LinkedInShare on LinkedIn

ARTICLE · 24 SEPTEMBER 2025

Benesch's Cannabis Industry Quarterly Update: Q3 2025

Benesch, Friedlander, Coplan & Aronoff LLP
Benesch, Friedlander, Coplan & Aronoff LLP
Contributor
Explore more from Benesch, Friedlander, Coplan & Aronoff LLP

A U.S. House subcommittee advanced a bill barring the DOJ from rescheduling cannabis, directly opposing the Biden administration's move to reclassify marijuana under the Controlled Substances Act...

United StatesCannabis & Hemp

Key Issues

Congress targets cannabis and hemp reforms amid DOJ, DEA, Tax clashes

A U.S. House subcommittee advanced a bill barring the DOJ from rescheduling cannabis, directly opposing the Biden administration's move to reclassify marijuana under the Controlled Substances Act. Simultaneously, both House and Senate appropriations committees approved measures to redefine hemp and ban most hemp-derived THC products, including delta-8 and THCA, sparking industry concerns. Meanwhile, the DEA has stalled its cannabis rescheduling appeal for over six months, citing administrative delays and leadership turnover. Lawmakers also passed an amendment allowing VA doctors to recommend medical cannabis, while a federal court ruled cannabis firms ineligible for pandemic-era tax credits. Lastly, Sen. Warren and Rep. Stansbury urged President Trump to end federal cannabis arrests and embrace reform.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from